{'fraction_non_alphanumeric': 0.022351797862001945, 'fraction_numerical': 0.023323615160349854, 'mean_word_length': 4.8192090395480225, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The changing epidemiology of Reye's syndrome in the United States: further evidence for a public health success.

A syndrome consisting of encephalopathy and fatty metamorphosis of the liver was first described by R. D. K. Reye et al 1 in Australia in 1962 and by George Johnson and coworkers 2 in the United States in 1963. In contrast to the cases reported by Reye et al—which occurred primarily in infants and young children (66% were ≤2 years of age) and had no distinct seasonality—the patients first described by Johnson et al were older (between 6 and 13 years of age) and the cases occurred during an outbreak of influenza B in a community in North Carolina. Despite these differences, the similarities of these two descriptions led to the common designation of this clinicopathological entity as Reye-Johnson or Reye's syndrome . Following its initial description, Reye's syndrome became increasingly recognized in the 1960s and 1970s in the United States as a distinct entity, occurring in association with outbreaks of